Hims Discontinued Compounded Semaglutide: What It Means and What to Do Next
If you were getting compounded semaglutide through Hims or Hers, you have probably already received notice that things are changing. In March 2026, Hims & Hers reached a settlement with Novo Nordisk e
In this article
*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting, stopping, or changing any medication or treatment program.*
---
If you were getting compounded semaglutide through Hims or Hers, you have probably already received notice that things are changing. In March 2026, Hims & Hers reached a settlement with Novo Nordisk ending its compounded GLP-1 advertising and marketing program. By May 2026, the company confirmed it was transitioning patients entirely to FDA-approved brand-name medications.
For the thousands of people who started their weight loss journey through Hims, this is disruptive. You found something that was working, and now you need to figure out what comes next.
This article explains what happened, why it matters, and what your options actually look like in 2026.
---
What Happened with Hims and Compounded Semaglutide?
The story starts with Novo Nordisk, the manufacturer of Wegovy and Ozempic.
In February 2026, Novo Nordisk sent a formal demand letter to Hims & Hers alleging patent infringement related to its compounded semaglutide products. Novo Nordisk then filed legal proceedings against the company. On March 9, 2026, both companies announced a settlement: Hims agreed to stop advertising and marketing compounded GLP-1 medications on its platform.
As part of the agreement, Hims shifted its primary offering to branded Novo Nordisk products, making injectable Wegovy, oral Wegovy, and other brand-name semaglutide options available to subscribers.
By May 2026, Hims confirmed the transition was complete for new patients. Existing patients on compounded protocols were being moved toward branded alternatives. New patients no longer have access to compounded semaglutide through Hims.
What Hims currently offers includes:
- Injectable Wegovy: approximately $299 per month
- Oral Wegovy: approximately $249 per month
- Zepbound (tirzepatide): approximately $399 per month
These prices reflect branded, FDA-approved medications, which carry a different cost structure than compounded versions.
*Compounded medications are not FDA-approved. This distinction matters for both regulatory and cost reasons.*
---
Why This Matters for Compounded GLP-1 Patients
Brand-name GLP-1 medications cost significantly more than compounded versions. For many people, the compounded price point was what made treatment accessible in the first place.
Not everyone has insurance that covers Wegovy or Ozempic. Without coverage, $249 to $399 per month is a meaningful jump from the $150 to $200 range where most compounded programs were priced.
If you are currently on compounded semaglutide from Hims, a few things matter:
Do not stop without talking to your provider. Abruptly stopping any GLP-1 medication can affect your progress and your metabolic health. Your prescribing clinician should be part of any transition decision. Contact Hims directly for guidance on your current protocol and consult a healthcare provider about your options going forward.
You have time to evaluate alternatives. The transition is not instantaneous for everyone. Use this window to understand what options are available rather than making a rushed decision.
Results are not guaranteed with any program. GLP-1 medications support weight loss as part of a comprehensive approach that includes nutrition and lifestyle changes. No medication guarantees a specific outcome, and individual results vary.
---
Options for Compounded Semaglutide in 2026
The Hims exit does not mean compounded semaglutide has disappeared from the market. Other licensed telehealth platforms continue to offer compounded GLP-1 programs through 503A-licensed compounding pharmacies.
Here are the main paths forward. This is not a ranking, and the right choice depends on your individual clinical situation, budget, and relationship with your current provider.
Option 1: Other Telehealth Platforms
Several telehealth companies continue to offer compounded semaglutide and tirzepatide programs through licensed 503A pharmacies. Prescriva, for example, offers compounded semaglutide starting at $169 per month and compounded tirzepatide starting at $269 per month. These programs include a free intake assessment, licensed clinician review by an independently licensed provider, and dispensing through a 503A-licensed compounding pharmacy.
When evaluating any telehealth platform offering compounded GLP-1s, ask specifically:
- Which pharmacy dispenses your medication, and does it hold a valid 503A license?
- Does a licensed clinician review your case before any prescription is written?
- Is the price you see all-inclusive, or are there separate consultation or shipping fees?
Option 2: Brand-Name GLP-1 Medications
If you have insurance coverage or are open to the higher price point, FDA-approved options include:
- Wegovy (semaglutide): available in injectable and oral formulations, FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition
- Ozempic (semaglutide): injectable, FDA-approved for type 2 diabetes management
- Zepbound (tirzepatide): injectable, FDA-approved for chronic weight management
- Foundayo (orforglipron): oral small-molecule GLP-1, FDA-approved in April 2026 for chronic weight management; available cash-pay through select telehealth and retail programs at approximately $149 per month at the time of writing
Option 3: Your Primary Care Physician
A primary care doctor or obesity medicine specialist can prescribe both brand-name GLP-1 medications and, in appropriate clinical circumstances, write prescriptions for compounded versions through an independent licensed 503A pharmacy. This route involves no platform intermediary and may work well if you have an established relationship with a trusted physician who is familiar with your history.
---
What to Look for in a Compounded GLP-1 Provider
If you choose to continue with compounded semaglutide through a different telehealth platform, these criteria should be non-negotiable:
503A-licensed pharmacy. The pharmacy dispensing your medication should hold a valid 503A license from its state board of pharmacy. This is distinct from a 503B outsourcing facility, which operates under different federal oversight standards. Ask for the pharmacy name and verify its licensure independently if you want to confirm.
Licensed clinician involvement. A licensed physician, nurse practitioner, or physician assistant should review your intake information, evaluate whether GLP-1 therapy is appropriate for your health situation, and sign off on the prescription. An online questionnaire alone, without clinician review, does not constitute proper medical oversight.
Transparent all-inclusive pricing. Consultation, medication, and standard shipping should be covered in the stated monthly cost. Watch for separate consultation fees, shipping charges, or medication-at-cost pricing that inflates the effective monthly total beyond the advertised number.
HIPAA-compliant data handling. Any platform receiving your health information and personal details is required to comply with HIPAA. Look for an explicit privacy notice and published information about data security practices before sharing your medical history.
---
About Prescriva
Prescriva is a telehealth platform specializing in compounded GLP-1 and peptide treatments. Compounded semaglutide starts at $169 per month. Compounded tirzepatide starts at $269 per month. Both programs include a free intake assessment, review by an independently licensed clinician, and dispensing through a licensed 503A compounding pharmacy.
If you are coming from Hims and evaluating your options, you can start with the free assessment at no cost and no obligation.
[Start Your Free Assessment](/get-started)
*Prescriva is a Management Services Organization (MSO) providing administrative and technology services only. Clinical decisions, prescriptions, and medical oversight are provided by independently licensed providers in our network. Compounded medications are not FDA-approved drugs. Results vary. This is not medical advice. Consult your healthcare provider before making any changes to your current treatment.*
---
Moving Forward
Losing access to a medication that was working is genuinely frustrating, especially when the reason is a legal and business dispute between two corporations. The good news is that compounded GLP-1 programs still exist through licensed platforms, the market is better regulated than it was two years ago, and there are legitimate paths forward that do not require you to pay brand-name prices.
The most important next step is not which platform you choose. It is making sure you do not stop your current treatment without professional guidance. Speak with a healthcare provider before making any changes to your medication routine.
---
*This article is for informational purposes only and does not constitute medical advice. Individual results vary. Prescriva is an MSO and does not practice medicine. Compounded medications are not FDA-approved. Always consult a licensed healthcare provider before starting, stopping, or changing any medication.*
*Sources: [CNBC, "Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs," March 9, 2026](https://www.cnbc.com/2026/03/09/novo-nordisk-ends-legal-proceedings-hims-hers-compounded-weight-loss-drugs.html). Novo Nordisk company statement, February 2026.*
Stay informed
Weekly research updates and health guides. No spam.
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →Continue reading
Semaglutide Nausea: Why It Happens and How to Manage It
Does Semaglutide Cause Thyroid Cancer? What the Research Actually Shows
